Trial Profile

A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 17 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs INCB 057643 (Primary) ; Abiraterone; Azacitidine; Gemcitabine; Paclitaxel; Rucaparib; Ruxolitinib
Indications Haematological malignancies; Lymphoma; Solid tumours
Focus Adverse reactions; First in man
Sponsors Incyte Corporation

Most Recent Events

01 Apr 2022 The number of treatment arms increased from 2 to 14.
16 Sep 2019 Results of pooled analysis published in the Clinical Cancer Research.
29 May 2019 Status changed from active, no longer recruiting to discontinued.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com